USA: Patients with cancer, transplants, or self-care will be the first to receive the CoVID-19 vaccine booster.


This was confirmed by Anthony Fauci, the White House chief of staff for infectious disease management. In addition, he called on Americans to be vaccinated against polio.

Anthony Fauci, the top US infectious disease management authority, said Sunday that Americans who are protected from immunizations may need to increase the COVID-19 vaccine. "Transplant patients, cancer chemotherapy, autoimmune patients, who have immune systems, are one of those people who, if there is a third development, which is likely to happen, will be among the first," Anthony Fauci said. During an interview on CNN.

Citing recent studies suggesting that immunizations may be reduced in vaccinated people, Fauci said the US Department of Health is reviewing data to determine when booster is needed. May be. "It's a dynamic situation. It's ongoing. It's evolving like many other epidemics," said Foucault, director of the National Institute for Allergy and Infectious Diseases. "You have to look at the data."

Last Thursday, a senior official at the Centers for Disease Control and Prevention (CDC) said the agency was exploring options for administering a third dose to patients with compromised immune systems before regulators could detect the corona virus. Allow emergency use for immunizations. The move could soon lead to a Pfizer vaccine.

Amanda Cohn, chief medical officer of the CDC's immunization division, told an agency's advisory committee that officials had "provided" access to booster shots "to some people" before any possible changes in decisions ". Actively looking for ways. " "So stay tuned," he added.

The growing consensus within the administration that at least some Americans will need a booster is tied in part to research suggesting that Pfizer's vaccine is less effective against the coronavirus after about six months. More than half of those vaccinated in the United States so far have received the Pfizer vaccine in two doses administered three weeks apart.

According to the company, Pfizer's ongoing global study of participants in its clinical trials shows that four to six months after the second dose, the vaccine's efficacy against symptomatic infection drops from a maximum of 95% to 84%.

Figures from the Israeli government, which has vaccinated more than half of its population since Pfizer's diet since January, also point to a declining trend over time. However, management officials carefully consider these figures due to the wide margin of error.

The latest figures from the Israeli Ministry of Health, released this weekend, suggest that the Pfizer vaccine was only 39 effective in preventing infection in the country in late June and early July. 95% during January to April.

The vaccine remained more than 90% effective in preventing severe disease and almost as effective in preventing hospitalization. As a result, Israel began offering a third dose of Pfizer to citizens with severely weakened immune systems on July 12.

People with compromised immune systems makeup 2.7% of the population, according to the CDC, and include those with cancer, organ or stem cell transplants, or infectious diseases, among others.


The United States will purchase another 200 million doses of Pfizer's COVID-19 vaccine to prepare for future needs, such as booster shots and vaccinations for children under 12.

White House Press Secretary Jen Psaki said Biden's administration wanted "maximum flexibility" to deal with the changing situation and would prepare for any emergency. "

This extra dose will be administered between the end of this year and the next.